In CLL, activity and tolerability at clinical level of the Btk inhibitor ibrutinib has led to its approval and has motivated numerous trials in combination with chemotherapy or immunotherapy [27]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.